Optometry's Charity™ |  Optometry's Meeting® |  AOA News |  Optometry's Career Center® |  Ask a Question  
AOA Home
About the AOA| Doctors| Paraoptometrics| Students & Educators| Health Care Policy Advocates| Media
  
< Ophthalmic Council™ 2009

Allergan



Allergan

Allergan is a PLATINUM level sponsor of the American Optometric Association.

Allergan

sponsors the following AOA programs:

As of January 2009

Optometry's Meeting®

  • AOSA Student Travel Grants
  • Exclusive Friday Education Program
  • Specialty OD Education Course
  • CLCS Student Research Award
  • Hotel/Venue Fact Sheet

Allergan offers and pursues innovative products to improve patient care.

With nearly 60 years of successfully discovering and developing new therapeutic agents to help protect and preserve vision, Allergan's heritage offers eye care professionals and patients a broad range of products to treat a variety of eye conditions.

As a result of dedicated research and development (R&D) efforts and close relationships with eye care professionals, Allergan has established itself as a global leader in eye care.

"As primary eye care providers, optometrists play a critical role in examining, diagnosing, treating and managing diseases and disorders of the eye," said Joseph J. Schultz, Allergan senior vice president, U.S., Eye Care. "At Allergan, we are proud to offer optometrists innovative therapeutics to provide their patients with quality vision and eye care."

Robust product offerings and pipeline

Allergan offers an extensive eye care portfolio for optometrists, including Restasis® (cyclosporine ophthalmic emulsion) 0.05%, the Refresh® brand line of artificial tears, Optive™ Lubricant Eye Drops, Optive™ Sensitive Preservative-Free Lubricant Eye Drops, Combigan® (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Lumigan® (bimatoprost ophthalmic solution) 0.03%, Alphagan® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%, Acular LS® (ketorolac tromethamine ophthalmic solution) 0.4%, Zymar® (gatifloxacin ophthalmic solution) 0.3% and Latisse™ (bimatoprost ophthalmic solution) 0.03%.

Looking to the future, Allergan's robust R&D programs are focused on the discovery of advanced therapies for glaucoma, ocular surface diseases and back-of-the-eye diseases such as macular edema, diabetic retinopathy and age-related macular degeneration - diseases that unfortunately cause sight loss in thousands of patients each years and whose prevalence is increasing as the population ages.

Consistent commitment to optometry

Allergan works closely with third-party optometry groups, key opinion leaders and managed care organizations to stay abreast of optometrists' needs and remains committed to providing support for optometrists at all levels with a dedicated sales force, continuing education programs and educational initiatives for teaching institutions.

"As a patient's first connection to eye health, optometrists around the country have shared with us the areas they feel are most important to their daily interactions with patients," said Paul King, manager, Optometric Strategies. "In 2009, we will continue to focus on supporting educational programs and delivering leading products that help optometrists improve patient outcomes and build their practices."

Allergan supports the AOA and American Academy of Optometry meetings, Vision Expos (East and West) and regional and local section meetings.